In persons with opioid use disorder, BZDs might also (e.g., via GABA interneurons on mu-opioid receptors) indirectly modulate mu-opioid receptor function (137), potentially leading to altered sensitivity to drug reinforcement (138). The gene discussed is OPRM1; the disease is opioid use disorder.